Congratulations! BiOptic has received the CE-IVD approval for SARS-CoV-2 Detection System

1. Date of Fact: 2022/3/21

2. Company Name: BiOptic Inc.

3. Relationship with the company (please enter the company or subsidiary): BiOptic Inc.

4. Mutual Shareholding Ratio: not applicable

5. Cause of occurrence: The coronavirus nucleic acid detection and analysis platform developed by BiOptic, is a Qexp-MDx Direct SARS-CoV-2 Detection Kit Utilizing self-developed and designed "Qsep1, Qsep1-Lite, Qsep100, Qsep400 Bio-Fragment Analyzer” and “Qamp mini Thermal Cycler”, have been audited to comply with EU regulations, Complete the self-declaration and registration procedures and obtain EU CE-IVD certification. This is a "no extraction" and uses "saliva" as an analytical method for analyzing samples.

6. Countermeasures: Not applicable

7. Other items to be stated: EU CE-IVD certification is a regulatory approval, but product sales still depend on the development of the epidemic and market supply and demand. Investors should make prudent judgments and invest prudently.

For more details: BiOptic LinkedIn Account